ADR Biomedical Holdings Inc.
ADR BioMedical Holdings Mid-Term Management Plan 2026-2028
ADR BioMedical Holdings has formulated a mid-term management plan for 2026-2028, aiming to expand sales from 750 million yen to 4.06 billion yen. The company plans to focus on new businesses and research & development to expand recurring revenue streams.
Key Figures
- Net Sales: 750 million yen (FY2026 forecast) → 4.06 billion yen (FY2028 forecast)
- Research data accumulation: approximately 3 times increase (comparison of horse implantation rates)
- Number of research-stage data: over 500 cases
AI要約
Overview of the Mid-Term Management Plan
ADR BioMedical Holdings has formulated a mid-term management plan for 2026-2028 with the goal of expanding net sales from approximately 750 million yen to 4.06 billion yen. The company aims to expand recurring revenue streams through research & development and new business development. Special emphasis is placed on expanding its product portfolio with proprietary technologies and accumulating research data, as well as strengthening collaborations with medical and research institutions.
Future Outlook and Strategy
The company plans to promote research data accumulation and new product development, leveraging low-risk autograft procedures and emerging research-stage technologies. The expansion of recurring revenue streams aims to establish a stable earnings foundation and achieve long-term growth. Additionally, the company will strengthen direct sales to medical institutions and collaborations with academic organizations to promote the practical application and commercialization of research data.
ADR BioMedical Holdings Inc.
Company overview · Stock price · Financial data · All IR
